Amunix Pharmaceuticals, Inc.
http://www.amunix.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amunix Pharmaceuticals, Inc.
Sanofi Looks To Dominate $5bn Hemophilia A Factor Market After Trial Success
Phase III success for efanesoctocog alfa sets up a filing in the near future, and a chance to seize market share from existing Factor VIII products, as well as Roche’s Hemlibra.
Sanofi Will Employ Adagene’s Technology For Precision Targeting In Cancer
Sanofi will pay $17.5m up front to license candidates developed with Adagene’s SAFEbody platform, which can mask antibodies, enabling them to reach cancer targets in the tumor microenvironment.
Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
J.P. Morgan Day 2: What's Next For Pharma, From Alzheimer's To Omicron
Daily notebook from the virtual J.P. Morgan Healthcare Conference: Alzheimer's rivals Roche and Lilly address their attempts at a different launch for their anti-amyloid therapies than Biogen's Aduhelm. GSK is buoyed by sotrovimab's efficacy against Omicron, BioNTech looks to the future of mRNA and Sanofi, Amgen and AbbVie defend their growth strategies.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Index Ventures
- Versartis Inc.
- Diartis Pharmaceuticals, Inc.